Daewoong Pharmaceutical “Continues to sell Botox products in the US”… The situation reversed in a day

Input 2021.02.16 12:19 | Revision 2021.02.16 12:21

The sale ban was announced today, but…
“US Court Allows Resumption of Sales Before Appeal”

Daewoong Pharmaceutical (069620)Announced on the 16th that the botulinum toxin (Botox) product’Nabota’ (US product name’Jubo’) will be able to continue sales in the United States. The situation changed one day after the news that US President Joe Biden approved Nabota’s decision to ban US imports the day before and that sales in the US were banned.

previously Medytox (086900)Claimed that Daewoong Pharmaceutical had stolen the technology of its Botox product and filed a complaint with the US International Trade Commission (ITC) to ban the sale of the product in the United States. In December of last year, the ITC accepted some of Medytox’s claims and ruled against importing Nabota for 21 months.

Medytox said the day before, “The US president finally approved the ITC’s decision and the sale of Nabota to the US was banned from the 16th.” As the provisional injunction application was cited, it was possible to resume sales without a gap.”

In the process of preparing for an appeal against the ITC ruling, Daewoong Pharmaceutical applied to the court to allow the sale of the product until the appeal result was reached. On this day, this application was accepted.

Daewoong Pharmaceutical said, “We welcome Ebolus (Daewoong Pharmaceutical’s US partner) to continue its business even during the appeal period. We will correct all legal and factual errors in the existing ITC decision and will surely win the appeal.” did.